Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Bi-Specific MAbS Market, and What Factors Will Drive It?

The market size of bi-specific MAbS has seen an accelerated increase in recent times. It is projected to escalate from $7.83 billion in 2024, reaching $9.05 billion in 2025, with a compound annual growth rate (CAGR) of 15.5%. Factors such as higher healthcare spending, boosted funds, and official government actions account for the historic period’s growth.

The market of bi-specific MAbS is projected to experience swift expansion in the forthcoming years, with an estimated valuation of $14.89 billion by 2029; this represents a compound annual growth rate (CAGR) of 13.3%. The expected growth over the forecast period is primarily due to the rising prevalence of cancer, growth in the elderly population, and increase in chronic diseases incidence. Key trends identified for the forecast period include technological advancements, product innovation, artificial intelligence emphasis, investment in targeted and combination therapy, as well as strategic collaborative efforts.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What External and Internal Drivers Are Contributing to the Growth of theBi-Specific MAbS Market?

The growth of the bispecific monoclonal antibodies market is anticipated to be driven by the increasing incidence of cancer and other chronic diseases during the forecast period. Developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders, bispecific monoclonal antibodies are believed to be more potent than monoclonal antibodies (moAbs). This is because they target two or more antigens on tumor cells to hinder the advancement of cancer. According to the American Cancer Society’s (ACS) Cancer Facts & Figures 2023 report, in 2023, there are predicted to be around 609,820 cancer-related fatalities in the USA. Consequently, the rising prevalence of cancer and other chronic diseases is projected to fuel demand for bi-specific MAbs as a highly efficient treatment option.

What Segment Types Define the Bi-Specific MAbS Market Structure?

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Bi-Specific MAbS Market?

Businesses in the bi-specific MAbs market are progressively investing in strategic measures such as alliances and partnerships to enhance their product range and broaden their geographic footprint. A strategic partnership is a synergy between two or more companies aimed at achieving mutual objectives or goals. For example, in October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical firms, formed an exclusive partnership to develop MGD024, a bispecific antibody targeting CD123 and CD3 developed using MacroGenics’ DART platform, along with two other bispecific research initiatives. Gilead has been granted exclusive licensing options for MGD024 as part of this collaboration, which is believed to hold promise for the treatment of multiple blood-related cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to alleviate cytokine-release syndrome (CRS) symptoms and facilitate periodic dosing, potentially resulting in more patient-centric care and superior clinical outcomes for AML and MDS patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

What Is the Definition of the Bi-Specific MAbS Market?

Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumor immunotherapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model